Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Chon on Challenges With Maintenance Therapy in Ovarian Cancer

February 20th 2020

Hye Sook Chon, MD, gynecologic oncologist, Moffitt Cancer Center, discusses challenges that are still faced in the maintenance setting in advanced ovarian cancer.

Dr. Penson on Biomarkers of Response to PARP Inhibitors in Ovarian Cancer

February 20th 2020

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Medicine, Massachusetts General Hospital, discusses prospective biomarkers that may predict response to PARP inhibitors in advanced ovarian cancer.

Dr. Hoffman on Primary Debulking Versus Neoadjuvant Chemotherapy in Ovarian Cancer

February 20th 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses eligibility criteria for primary debulking surgery versus neoadjuvant chemotherapy in advanced ovarian cancer.

If Only That Phase III Oncology Trial Had Been Designed Differently

February 19th 2020

The cancer treatment community's ultimate perception of a successfully completed phase III randomized trial depends in large part on how well the trial was conceived and structured. To permit adequate accrual in a timely manner and optimize the chances for a study to achieve success, the question it poses must be relevant to ensure interest by clinical investigators, referring clinicians, and potential research subjects. Further, the initiative must have adequate funding for data collection and analysis, translational laboratory investigations, and other trial components.

Dr. Fowler on Patient Eligibility for Cytoreductive Surgery in Ovarian Cancer

February 19th 2020

Jeffrey M. Fowler, MD, discusses patient eligibility for cytoreductive surgery in newly diagnosed ovarian cancer.

Dr. Wenham on Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in Ovarian Cancer

February 19th 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, sheds light on the debate between neoadjuvant chemotherapy and primary debulking surgery in patients with newly diagnosed, advanced ovarian cancer.

Somatic Testing Could Be Standard Approach in Endometrial Cancer

February 18th 2020

Julia Fehniger, MD, discusses emerging strategies in the treatment paradigm for patients with BRCA1/2-mutant endometrial cancer.

Niraparib Plus Radiotherapy Explored in Metastatic Cervical Cancer

February 18th 2020

Investigators are exploring concurrent PARP inhibition and definitive regional radiotherapy in patients with metastatic invasive cervical cancer in an ongoing phase I/II study.

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian Cancer

February 14th 2020

Kathleen Moore, MD, discusses topline findings from the phase III FORWARD I/GOG 3011 trial in ovarian cancer.

Dr. Berger on Chemotherapy Delivery Options in Ovarian Cancer

February 13th 2020

Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.

Optimal Testing Methods in Ovarian Cancer

February 12th 2020

Leigha Senter, MS, LGC, discusses optimal testing methods in ovarian cancer.

Dr. Copeland on the Use of PARP Inhibitors in Ovarian Cancer

February 11th 2020

Larry J. Copeland, MD, professor, Obstetrics & Gynecology, College of Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the use of PARP inhibitors in ovarian cancer.

Dr. Backes on Experience With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.

Dr. Secord on Financial Toxicity Associated With PARP Inhibition

February 10th 2020

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

Secord Shares Data to Digest With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

Dr. Hagemann on Best Practices for Pathology in Gynecologic Cancers

February 9th 2020

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers

February 9th 2020

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

Immunotherapy Shows Promise in Cervical Cancer Treatment

February 9th 2020

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

Dr. Secord on the Role of PARP Inhibitors in Ovarian Cancer

February 9th 2020

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Dr. Langstraat on Sentinel Lymph Nodes for Endometrial Cancer

February 9th 2020

Carrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.